Observational study in Pathogens (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
María Leonor Fernández-MurgaMolecular Oncology Laboratory, Arnau de Vilanova Hospital, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), 46015 Valencia, Spain.ORCID 0000-0001-7123-9834
Lucía Serrano-GarcíaMolecular Oncology Laboratory, Arnau de Vilanova Hospital, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), 46015 Valencia, Spain.ORCID 0009-0009-2509-1176
Giuseppe D'AuriaSequencing and Bioinformatics Service, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), Avda. de Catalunya 21, 46020 Valencia, Spain.ORCID 0000-0003-0672-2541
María Portero HernándezMolecular Oncology Laboratory, Arnau de Vilanova Hospital, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), 46015 Valencia, Spain.
Llúcia Martínez-PriegoSequencing and Bioinformatics Service, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), Avda. de Catalunya 21, 46020 Valencia, Spain.ORCID 0000-0002-1073-269X
Loreto Ferrús-AbadSequencing and Bioinformatics Service, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), Avda. de Catalunya 21, 46020 Valencia, Spain.
Griselda de MarcoSequencing and Bioinformatics Service, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), Avda. de Catalunya 21, 46020 Valencia, Spain.
María Victoria Domínguez-MárquezMicrobiology Department, Arnau de Vilanova Hospital, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), 46015 Valencia, Spain.
Antonio Llombart-CussacMolecular Oncology Laboratory, Arnau de Vilanova Hospital, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), 46015 Valencia, Spain.ORCID 0000-0003-4515-8293
Funding
Consellería de Sanitat Universal i Salut Pública (Generalitat Valenciana, Spain and the EU Operational Program of the European Regional Development Fund (ERDF) for the Valencian Community 2014-2020, within the framework of the REACT-EU programme, as the U 2014-2020
6 · The paper itself
Abstract
Understanding the immune response to SARS-CoV-2 vaccination in cancer patients remains a critical priority given their immunocompromised status. In this prospective observational study, we evaluated humoral and cellular immunity across three time points-baseline, post-second dose, and post-booster-in 23 breast cancer patients undergoing active treatment. IgG antibody levels showed a significant increase following vaccination, with a 300-fold rise after the second dose and a 2200-fold increase post-booster, indicating a strong humoral response. CD19
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Immunogenicity of SARS-CoV-2 mRNA Vaccine in Breast Cancer Patients Undergoing Active Treatment: A Prospective Observational Study. · full record | OpenQuestion